BT317 defines an emerging class of LonP1 and CT-L inhibitors that exhibited promising anti-tumor activity and could be a potential candidate for malignant astrocytoma therapeutics. The gene discussed is LONP1; the disease is astrocytoma (excluding glioblastoma).